消化器疾患治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Gastrointestinal Therapeutics Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01:Executive summary
• Highlights

PART 02:Scope of the report
• Market overview
• Top-vendor offerings

PART 03:Market research methodology
• Research methodology
• Economic indicators

PART 04:Introduction
• Key market highlights

PART 05:Pipeline portfolio
• Ulcerative colitis
• Crohn’s disease
• IBS

PART 06:Market landscape
• Global gastrointestinal therapeutics market

PART 07:Market segmentation by disease type
• Overview

PART 08:Global IBD therapeutics market
• Global ulcerative colitis drugs market
• Global Crohn’s disease drugs market
• Market segmentation by molecule type

PART 09:Global IBS therapeutics market

PART 10:Global gastrointestinal OTC drugs market

PART 11:Geographical segmentation
• Global gastrointestinal therapeutics market by geography 2015-2020
• Gastrointestinal therapeutics market in Americas
• Gastrointestinal therapeutics market in EMEA
• Gastrointestinal therapeutics market in APAC

PART 12:Market drivers
• Increasing consumption of biologics
• Tentative approval of late stage molecules
• Development of novel therapies using innovative technologies
• Improved diagnostic tools increasing the treatment-seeking population

PART 13:Impact of drivers

PART 14:Market challenges
• Increased consumption of OTC medications
• Unknown etiology of IBD and IBS
• Discontinuation of drugs under development and from the market

PART 15:Impact of drivers and challenges

PART 16:Market trends
• Patient assistance programs
• Emergence of biosimilars
• Rise in self-medication
• Focus on regenerative medicines
• Strategic alliances and M&A

PART 17:Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 18:Key vendor analysis
• AbbVie
• Johnson & Johnson
• Takeda
• Allergan
• UCB

PART 19:Appendix
• List of abbreviations

PART 20:Explore Technavio

[List of Exhibits]

Exhibit 01:Product offerings
Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015
Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments
Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio
Exhibit 05:Global Crohn’s disease therapeutics market: Pipeline portfolio
Exhibit 06:Global IBS therapeutics market: Pipeline portfolio
Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
Exhibit 09:Approval and patent expiries of top selling biologics
Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions)
Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
Exhibit 12:Five forces analysis
Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015
Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020
Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015
Exhibit 17:Global IBD therapeutics market by type 2015-2020
Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis
Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions)
Exhibit 20:Global Crohn’s disease drugs market 2015-2020 ($ billions)
Exhibit 21:Global IBD therapeutics market by molecule type 2015
Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions)
Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US
Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020
Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020
Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015
Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015
Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas
Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA
Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC
Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market
Exhibit 41:Biologics for IBD: market share 2012-2022
Exhibit 42:Few biologics under development for gastrointestinal disorders
Exhibit 43:Impact of drivers
Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors
Exhibit 45:Gastrointestinal therapeutics discontinued from development or market
Exhibit 46:Impact of drivers and challenges
Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends
Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US
Exhibit 49:Biosimilars under development for gastrointestinal disorders
Exhibit 50:Regenerative medicines for IBD under development
Exhibit 51:Key vendors ranking 2015
Exhibit 52:Key vendors: Geographical presence
Exhibit 53:Market vendors: Competitive scenario 2015-2020
Exhibit 54:AbbVie: Profile
Exhibit 55:AbbVie: Strength analysis
Exhibit 56:AbbVie: Growth strategy matrix
Exhibit 57:AbbVie: Opportunity assessment
Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
Exhibit 59:Johnson & Johnson: Profile
Exhibit 60:Johnson & Johnson: Strength analysis
Exhibit 61:Johnson & Johnson: Growth strategy matrix
Exhibit 62:Johnson & Johnson: Opportunity assessment
Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 65:Takeda: Profile
Exhibit 66:Takeda: Strength analysis
Exhibit 67:Takeda: Growth strategy matrix
Exhibit 68:Takeda: Opportunity assessment
Exhibit 69:Allergan: Profile
Exhibit 70:Allergan: Strength analysis
Exhibit 71:Allergan: Growth strategy matrix
Exhibit 72:Allergan: Opportunity assessment
Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
Exhibit 74:UCB: Profile
Exhibit 75:UCB: Strength analysis
Exhibit 76:UCB: Growth strategy matrix
Exhibit 77:UCB: Opportunity assessment


【レポート販売概要】

■ タイトル:消化器疾患治療薬の世界市場2016-2020
■ 英文:Global Gastrointestinal Therapeutics Market 2016-2020
■ 発行日:2016年9月30日
■ 調査会社:Technavio
■ 商品コード:IRTNTR10476
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。